Author of

• 17629

  +

  P2.03b - Poster Session with Presenters Present (ID 465)

  • Event: WCLC 2016
  • Type: Poster Presenters Present
  • Track: Advanced NSCLC
  • Presentations: 1
  • Moderators:
  • Coordinates: 12/06/2016, 14:30 - 15:45, Hall B (Poster Area)

  • 17631

    +

    P2.03b-002 - Efficacy and Safety of WBRT Combined with Endostar in Patients with Advanced Non-Small Cell Lung Cancer (ID 5703)

    14:30 - 14:30  |  Author(s): P. Liu
    • Abstract

    Background:
    We aimed to identify the optimal regimen of endostar combined with whole brain irradiation(WBRT) for BM for evaluation and provide preliminary efficacy data.
    
    Methods:
    The 30 cases of advanced NSCLC patients with symptomatic unresectable BM were randomly divided into two groups, experimental group (15 cases): the Endostar (15 mg/m[2], intravenous infusion, d1-7) synchronization of WBRT (40 Gy/20 fractions/4 weeks); control group (15 cases): WBRT alone. Cerebral blood volume (CBV), blood flow (CBF) and mean perfusion time (MTT) and lymphocyte analysis were observed by magnetic resonance perfusion imaging before and 4 weeks after WBRT.
    
    Results:
    In experimental group, CBF, CBV and MTT at baseline were 582.12±161.42, 524.00±428.64 and 235.00±149.36. Four weeks after treatment, those perfusion values were 260.00±356.6, 336.00±480.82 and 509.00±44.34 respectively, which showed obvious decreasing trends compared with baseline data in CBF and CBV, while increased in MTT(Fig 1). Figure 1 Figure 1 The measurement of MR perfusion imaging of brain. Figure 2 Figure 2: Immune function related indicators. All the ten cases showed a partial response (PR) to therapy in experimental group, while in the control group the response rate was 40%.Endostar in combination with WBRT was generally well tolerated.
    
    
    
    
    
    Conclusion:
    Endostar combined with WBRT appears to be a efficacy and tolerable treatment of BM.